Drug giant Merck’s net income increased more than 80 per cent to $5.8bn in the last quarter, as its top-selling cancer drug hit record sales.
Sales of Merck’s blockbuster drug Keytruda rose 10 per cent to $8.1bn in the three months to the end of September, up from $7.4bn from the same period a year ago, the company said on Thursday.
Merck edged up its full-year earnings guidance range to $8.93-$8.98 a share, from its previous forecast of $8.87-$8.97.
您已阅读23%（453字），剩余77%（1551字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。